---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-26-000104"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2026-08-31T20:18:04+00:00"
generated_at: "2026-08-31T20:19:37.628573+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Federal Circuit affirms Exelixis patents; generic competitor blocked until Jan 15, 2030

## Summary
- Court of Appeals affirmed validity of U.S. Patent Nos. 11,091,439, 11,091,440, 11,098,015.
- FDA approval of MSN's ANDA effective no earlier than Jan 15, 2030, subject to appeals and exclusivity.
- MSN's appeal on patent 11,298,349 dismissed as moot; that ruling vacated.
- Separate litigation on patent 12,128,039 (expires Feb 2032) with trial set for Nov 2026.
- Outcome protects Exelixis from generic competition until at least 2030.

## SEC filing metadata
- accession: 0000939767-26-000104
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2026-08-31T20:18:04+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/0000939767-26-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/exel-20260831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-26-000104
- JSON: https://secwatch.observer/filing/0000939767-26-000104.json
- Plain text: https://secwatch.observer/filing/0000939767-26-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.